Clinical trials: Endocrine System Disorder
Ovarian Neoplasms, Ovarian Cancer
AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer
The main purpose of this study is to determine if AZD0530 can improve the efficacy of standard chemotherapy for the treatment of ovarian cancer
- Trial name
- OVERT-1 (NCT00610714)
- Testing
- AZD0530, Carboplatin, Paclitaxel
- Where
- 50 sites in Bulgaria, Canada and 10 more
- Volunteers
- 211 people
- Sponsor
- AstraZeneca
Diabetes, Healthy
A Trial Investigating the Absolute Bioavailability of Insulin Degludec in Healthy Subjects
This trial is conducted in Europe. The aim of the trial is to investigate the absolute bioavailability of insulin degludec (IDeg) in healthy subjects.
- Trial name
- NCT01623375
- Testing
- insulin degludec
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg
A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-398
- Trial name
- NCT04869800
- Testing
- CKD-398, CKD-501, D745
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Cushing Syndrome
A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome
This is a Phase 2 multicenter, randomized, double-blind, placebo controlled study of ATR-101 to evaluate the efficacy and safety of orally-administered ATR-101 in adults with endogenous Cushing's syndrome.
- Trial name
- NCT03053271
- Testing
- ATR-101
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 4 people
- Sponsor
- Millendo Therapeutics US, Inc.
Melanoma, Prostate Cancer
An Expanded Access Program for AM0010 (Pegilodecakin)
This is an Expanded Access Program (EAP) available to patients who have advanced cancers, who have failed or progressed on standard of care systemic therapy and do not qualify for ongoing clinical trials.
- Conditions
- Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma
- Trial name
- NCT03554434
- Testing
- AM0010
- Sponsor
- Eli Lilly and Company
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04389632
- Testing
- sigvotatug vedotin, pembrolizumab, cisplatin
- Where
- 158 sites in United States, France and 5 more
- Volunteers
- 1,006 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Cardiovascular Disease, Diabetes Mellitus, Type 2
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
The purpose of this trial is to assess whether dulaglutide can reduce major cardiovascular events and other serious outcomes in persons with type 2 diabetes, when added to their anti-hyperglycemic regimen.
- Trial name
- REWIND (NCT01394952)
- Testing
- Dulaglutide
- Where
- 300 sites in United States, Argentina and 23 more
- Volunteers
- 9,901 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)
The purpose of this clinical study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
- Trial name
- NCT00087516
- Testing
- Sitagliptin (MK0431), Sitagliptin, Metformin - Rescue
- Volunteers
- 741 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to Placebo during long term treatment (52 weeks and longer) in combination with basal insulin…
- Trial name
- NCT00954447
- Testing
- Linagliptin
- Where
- 169 sites in United States, Argentina and 17 more
- Volunteers
- 1,263 people
- Sponsor
- Boehringer Ingelheim
Metastatic Pancreatic Adenocarcinoma
Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma
The primary objective of this study is to compare the efficacy of GEM plus Z-360 versus GEM plus placebo on the overall survival (OS) in subjects with metastatic Pancreatic Adenocarcinoma.
- Trial name
- ZIPANG (NCT02117258)
- Testing
- Z-360
- Where
- 3 sites in Japan, South Korea and 1 more
- Volunteers
- 167 people
- Sponsor
- Zeria Pharmaceutical
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Diabetic Neuropathy, Painful
Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain
This study is to compare the tolerability of different methods for switching from another medication to duloxetine for the management of diabetic nerve pain.
- Trial name
- NCT00266643
- Testing
- duloxetine hydrochloride
- Where
- 20 sites in United States, Puerto Rico
- Volunteers
- 205 people
- Sponsor
- Eli Lilly and Company
Trisomy 21, Trisomy 18
Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood
The purpose of this study is to collect maternal blood samples from pregnant women carrying a fetus with a confirmed diagnosis of chromosomal abnormality or genetic disorder including microdeletions in order to further develop a…
- Conditions
- Trisomy 21, Trisomy 18, Trisomy 13, Sex Chromosome Abnormalities
- Trial name
- MAPS (NCT01852708)
- Where
- 9 sites in United States, Spain and 1 more
- Volunteers
- 1,059 people, healthy volunteers welcome
- Sponsor
- Natera, Inc.
Ovarian Carcinoma, Recurrent Endometrial Carcinoma
Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma
The folate receptor is overexpressed in many types of cancer, including ovarian and endometrial cancer, and the level of folate receptor expression increases with the stage of the disease.
- Trial name
- NCT01689714
- Testing
- Tc 99m EC20
- Volunteers
- 16 people
- Sponsor
- Endocyte
Type 2 Diabetes
A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
This is a multicenter, randomized, double-blind, active-controlled, parallel-group study, which aims to provide data on the efficacy and safety of HDM1002 tablets compared with dapagliflozin in adults with type 2 diabetes…
- Trial name
- NCT07082114
- Testing
- HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus
Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes
The purpose of this study is to compare Muraglitazar and Pioglitazone in patients with Type 2 Diabetes. Both the safety and blood sugar lowering effects of these treatments will be studied.
- Trial name
- NCT00106808
- Testing
- Muraglitazar, Pioglitazone
- Where
- 195 sites in United States, Argentina and 12 more
- Volunteers
- 1,440 people
- Sponsor
- Bristol-Myers Squibb
Pancreatic Cancer, Neoplasm Metastasis
Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas
The purpose of this study is to assess the 6-month survival rate and safety of talabostat and gemcitabine in patients with stage IV adenocarcinoma of the pancreas.
- Conditions
- Pancreatic Cancer, Neoplasm Metastasis, Adenocarcinoma
- Trial name
- NCT00116389
- Testing
- talabostat mesylate tablets, gemcitabine
- Where
- 28 sites in United States
- Volunteers
- 60 people
- Sponsor
- Point Therapeutics
Type 1 Diabetes (T1D), Type 1 Diabetes Mellitus
Twiist Postmarket Surveillance Study for Type 1 Diabetes
The goal of this surveillance study is to collect real-world data on adults and youth with type 1 diabetes (T1D) using twiist(TM) for insulin delivery.
- Trial name
- twiist-PS (NCT07356089)
- Testing
- twiist Automated Insulin Delivery System
- Where
- United States
- Volunteers
- 1,875 people
- Sponsor
- Deka Research and Development
Type II Diabetes Mellitus
Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients
The purpose of this study is to evaluate the effect of JTT-654 on diabetes as well as the safety, tolerability and pharmacokinetics of JTT-654 in type 2 diabetic patients.
- Trial name
- NCT00997152
- Testing
- JTT-654
- Where
- 42 sites in United States
- Volunteers
- 152 people
- Sponsor
- Shionogi Inc.
Obesity, Smoking
Africa and Middle East Cardiovascular Epidemiological Study
This is a cross-sectional, epidemiological study to determine the prevalence of cardiovascular risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension in patients attending General Practice clinics…
- Conditions
- Obesity, Smoking, Dyslipidemia, Diabetes Mellitus
- Trial name
- ACE (NCT01243138)
- Where
- 73 sites in Algeria, Cameroon and 12 more
- Volunteers
- 4,386 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.